CLASS II Device recall · Reported 18 Aug 2021 · FDA Enforcement Report

Etest Imipenem Relebactam recalled by Biomerieux

Biomerieux is recalling Etest Imipenem Relebactam, distributed nationwide in the US. The recall was initiated on 24 Jun 2021 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesRef 420927 (US Product) Lot numbers 1007888860, 1008598340, 1008701580, 1007607290, 1007888870, 1008390030, 1008598350 and 1008701590 and Ref 420925 (not distributed in US):Lot Codes: 1007888860, 100859840 and 1008701580
Quantity recalled1,431

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-2226-2021
FDA event ID
88242
Recalling firm
Biomerieux, Hazelwood, MO
Classification
Class II
Status
Terminated
Recall initiated
24 Jun 2021
FDA classified
6 Aug 2021
Reported
18 Aug 2021
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Sterility

Timeline

24 Jun 2021Recall initiated by company
6 Aug 2021Classified by FDA+43 days
18 Aug 2021Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Major errors (Resistant result instead of Susceptible result) were observed with Pseudomonas aeruginosa strains.

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

ETEST IMIPENEM RELEBACTAM. in vitro diagnostic

Where it was distributed

Worldwide distribution - US Nationwide distribution including in the states of AR, AZ, CA, CO, DE, FL, GA, IL, IN, KS, KY, MA, MD, ME, MI, MN, MO, NC, NE, NH, NJ, NV, NY, OH, OK, PA, SC, TN, TX, UT, VA, WA, WI, WV and Hawaii. The countries of Austria, Belgium, Croatia, Czech Republic, France, Germany, Greece, Italy, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland and United Kingdom.

Nationwide ArkansasArizonaCaliforniaColoradoDelawareFloridaGeorgiaHawaiiIllinoisIndianaKansasKentuckyMassachusettsMarylandMaineMichiganMinnesotaMissouriNorth CarolinaNebraska

Questions about this recall

Why was it recalled?

Major errors (Resistant result instead of Susceptible result) were observed with Pseudomonas aeruginosa strains.

Which lots are affected?

Ref 420927 (US Product) Lot numbers 1007888860, 1008598340, 1008701580, 1007607290, 1007888870, 1008390030, 1008598350 and 1008701590 and Ref 420925 (not distributed in US):Lot Codes: 1007888860, 100859840 and 1008701580

Where was it sold?

Worldwide distribution - US Nationwide distribution including in the states of AR, AZ, CA, CO, DE, FL, GA, IL, IN, KS, KY, MA, MD, ME, MI, MN, MO, NC, NE, NH, NJ, NV, NY, OH, OK, PA, SC, TN, TX, UT, VA, WA, WI, WV and Hawaii. The countries of Austria, Belgium, Croatia, Czech Republic, France, Germany, Greece, Italy, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland and United Kingdom.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Biomerieux

All 476

Other Test Kits & Diagnostics recalls

All 2,656